← Back to Home

Siemens Healthineers launches diagnostics carve-out, with Olyrian transformation expected to be completed by mid-2028

The diagnostics business, which manufactures more than 16 billion tests annually, will enter its next phase under an independent brand. But amid weakness in the Chinese market and pressure to improve profitability, the new company must still navigate cost and operational restructuring.

By SURL BioNews

The supplier behind testing systems that run daily in hospital laboratories is embarking on an organizational restructuring. On November 5, Siemens Healthineers announced the launch of a carve-out of its in vitro diagnostics business, which will gradually adopt the name Olyrian Diagnostics in preparation for becoming an independent company. The business manufactures more than 16 billion tests annually, and its transformation also affects an extensive network of medical testing supplies and services.

According to the company’s announcement, the transformation is expected to be completed by mid-2028, with Olyrian remaining part of Siemens Healthineers during the transition. The company said there are currently no changes to products and services, contracts, service levels or customer contacts. For healthcare institutions using existing systems, this is the most immediate commitment at this stage; branding and organizational changes will proceed gradually.

Olyrian’s scope covers laboratory automation, information systems and point-of-care testing. In vitro diagnostics obtains information about disease and health from human specimens. Beyond testing itself, it also relies on sample processing, interpretation of results and information transfer. Whether the new organization can maintain coordination across these steps offers a practical way to assess the transformation’s effectiveness.

The carve-out also comes amid business pressures. Reuters reported that the diagnostics division accounts for approximately 17% of group revenue and 20% of its total workforce, and has recently been affected by market weakness following healthcare reforms in China and by its transformation program. The division’s fourth-quarter adjusted EBIT margin was 5.4%, and it is targeting an additional €400 million in savings, indicating that preparations for independent operations must proceed alongside improvements in profitability.

Costs will not disappear immediately when the organization is separated. According to Reuters, citing Chief Financial Officer Jochen Schmitz, the carve-out will incur execution expenses in the short term, as well as costs that remain in the original organization after the business is moved out. Management expects more focused businesses to emerge over the long term, but until then, cost savings and transformation expenses will appear on the books at the same time.

Another strand of change concerns the group’s own name. Dow Jones Newswires reported that Siemens Healthineers plans to rename itself Healthineers, with the brand transition expected to begin in 2027 and run for three years, alongside the diagnostics division’s renaming. The two have separate timelines, and the mid-2028 deadline for the diagnostics transformation should not be taken as the completion date for all of the group’s branding changes.

What can currently be confirmed is that the diagnostics business has a new name and a transformation timetable; the announcement did not provide sufficient information to determine the final transaction structure or terms. For healthcare institutions, the more substantive issues ahead are whether product supplies, maintenance support and testing services can remain stable, and how cost restructuring will be implemented in operations.

References

  1. Siemens Healthineers
  2. Reuters via MarketScreener
  3. Dow Jones Newswires via MarketScreener